Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
Type:
Grant
Filed:
June 21, 2018
Date of Patent:
January 5, 2021
Assignee:
GILEAD SCIENCES, INC.
Inventors:
Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
Abstract: Methods and pharmaceutical compositions for preventing, treating or suppressing symptoms of a disorder associated with an alphavirus infection. In particular, the present invention relates to preventing, treating or suppressing symptoms of a disorder associated with an alphavirus infection through inhibiting the activity and/or expression of Transforming Growth Factor Beta (TGF-?) in a subject suffering from or at risk for suffering from an alphavirus infection.
Type:
Grant
Filed:
May 18, 2016
Date of Patent:
January 5, 2021
Assignee:
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Inventors:
Janko Nikolich-Zugich, Jennifer Uhrlaub
Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
Type:
Grant
Filed:
August 20, 2018
Date of Patent:
December 22, 2020
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
William Messer, Ralph Baric, Aravinda de Silva, Boyd Yount
Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
Type:
Grant
Filed:
October 24, 2016
Date of Patent:
December 1, 2020
Assignee:
INSTITUT PASTEUR
Inventors:
Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
Abstract: The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compositions comprising the vaccine vectors.
Type:
Grant
Filed:
February 2, 2012
Date of Patent:
December 1, 2020
Assignees:
Thomas Jefferson University, The United States of America, as Represented by the Secretary, Department of Health and Human Services Services
Inventors:
Joseph E. Blaney, Jason Paragas, Peter Jahrling, Reed Johnson, Matthias Schnell
Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).
Type:
Grant
Filed:
July 25, 2017
Date of Patent:
November 24, 2020
Assignee:
ALTOR BIOSCIENCE, LLC
Inventors:
Marilyn Fernandez, Bai Liu, Warren Marcus, Hing C. Wong
Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
Type:
Grant
Filed:
June 21, 2018
Date of Patent:
November 17, 2020
Assignee:
GILEAD SCIENCES, INC.
Inventors:
Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies may be characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
Type:
Grant
Filed:
September 12, 2017
Date of Patent:
November 17, 2020
Assignees:
Theraclone Sciences, Inc., The Scripps Research Institute, International AIDS Vaccine Initiative
Inventors:
Po-Ying Chan-Hui, Katherine Doores, Michael Huber, Stephen Kaminsky, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Majorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
November 10, 2020
Assignees:
Massachusetts Institute of Technology, National University of Singapore
Inventors:
Ram Sasisekharan, Kannan Tharakaraman, Kuan Rong Chan, Satoru Watanabe, Subhash G. Vasudevan, Eng Eong Ooi
Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
Type:
Grant
Filed:
July 24, 2018
Date of Patent:
October 27, 2020
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter D. Kwong, Gary J. Nabel, Rebecca S. Rudicell, John Mascola, Mark Connors, Ivelin Georgiev, Jiang Zhu, Young Do Kwon, Tongqing Zhou, Yongping Yang, Baoshan Zhang, Gwo-Yu Chuang, Xueling Wu, Zhi-yong Yang, Wei Shi
Abstract: The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes.
Type:
Grant
Filed:
August 4, 2016
Date of Patent:
October 27, 2020
Assignee:
INSTITUTE FOR ADVANCED STUDY
Inventors:
Raul Rabadan, Michael Krasnitz, Harlan Robins, Daniela Witten, Arnold Levine
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
Type:
Grant
Filed:
January 9, 2018
Date of Patent:
October 20, 2020
Assignees:
THE JOHNS HOPKINS UNIVERSITY, LIFE TECHNOLOGIES CORPORATION
Abstract: The present invention provides novel scaffolded HIV-1 vaccine immunogens. Some of the scaffolded immunogens contain a soluble gp140 trimer linked to the N-terminus of the nanoparticle subunit and a T-helper epitope that is fused via a short peptide spacer to the C-terminus of the nanoparticle subunit. Some other immunogens of the invention contain a soluble gp140 trimer protein that is linked to a stable nanoparticle via a short peptide spacer that is a T-helper epitope. Some of the scaffolded immunogens contain a gp140 trimer immunogen presented on a nanoparticle platform formed with I3-01 protein, E2p, or variants of protein 1VLW. Also provided in the invention are nucleic acids that encode the various vaccine immunogens described herein, and expression vectors and host cells harboring the nucleic acids. The invention further provides methods of using the scaffolded HIV-1 vaccine immunogens for preventing or treating HIV infections.
Abstract: The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins. When the promoter used is specific for terminally differentiated epithelial cells, then the viral envelope proteins will be expressed only in the upper part of the epithelia and therefore, stimulate the immune response. The infected epithelial stem cells in the basal layer will continue to produce new antigen-expressing cells, without being eliminated by the immune response. This invention will be useful in the development of vaccines against viral agents that target the internal mucosa like HIV.
Abstract: Stable immunogens comprising portions of the inner domain (ID) of the Human Immunodeficiency Virus (HIV-1) gp120 protein are provided. These ID immunogens selectively present the gp120 C1/C2 region in its CD4-bound state within a minimal structure. These ID immunogens can be used to vaccinate subjects against infection with HIV, the causative agent of Acquired Immunodeficiency Syndrome (AIDS). The immunogens can also be used as targets in screening to identify small molecule or peptide inhibitors that block HIV-1 viral entry and attachment steps, and as probes for identifying gp120 C1/C2 region-specific antibodies.
Type:
Grant
Filed:
August 19, 2015
Date of Patent:
August 4, 2020
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE
Inventors:
Marzena Pazgier, George Lewis, William Tolbert, Neelakshi Gohain
Abstract: The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
Type:
Grant
Filed:
October 5, 2016
Date of Patent:
August 4, 2020
Assignee:
Universitätsmedizin Der Johannes Gutenberg-Universität Mainz
Inventors:
Franz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
Abstract: Disclosed herein are recombinant baculoviruses suitable for detecting the presence of arthropod-borne viruses in a biological sample of a test subject. The information derived from the detection may also be used to render a diagnosis on whether the test subject is infected with the arthropod-borne viruses or not, so that proper course of treatment may be assigned to the subject.
Abstract: The invention features stabilized human immunodeficiency virus (H IV) clade C envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV clade C Env trimers. In addition, the invention features methods of making and using the stabilized HIV clade C Env trimers of the invention.
Type:
Grant
Filed:
October 3, 2014
Date of Patent:
July 21, 2020
Assignee:
Beth Israel Deaconess Medical Center, Inc.